Browse by author
Lookup NU author(s): Dr Gary ReynoldsORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2023 The Author. Immunological Reviews published by John Wiley & Sons Ltd. Immune checkpoint inhibitors are now an established treatment in the management of a range of cancers. Their success means that their use is likely to increase in future in terms of the numbers of patients treated, the indications and the range of immune checkpoints targeted. They function by counteracting immune evasion by the tumor but, as a consequence, can breach self-tolerance at other sites leading to a range of immune-related adverse events. Included among these complications are a range of rheumatologic complications, including inflammatory arthritis and keratoconjunctivitis sicca. These superficially resemble immune-mediated rheumatic diseases (IMRDs) such as rheumatoid arthritis and Sjogren's disease but preliminary studies suggest they are clinically and immunologically distinct entities. However, there appear to be common processes that predispose to the development of both that may inform preventative interventions and predictive tools. Both groups of conditions highlight the centrality of immune checkpoints in controlling tolerance and how it can be restored. Here we will discuss some of these commonalities and differences between rheumatic irAEs and IMRDs.
Author(s): Reynolds G
Publication type: Review
Publication status: Published
Journal: Immunological Reviews
Year: 2023
Volume: 318
Issue: 1
Pages: 51-60
Print publication date: 01/09/2023
Online publication date: 12/07/2023
Acceptance date: 26/06/2023
ISSN (print): 0105-2896
ISSN (electronic): 1600-065X
Publisher: John Wiley and Sons Inc
URL: https://doi.org/10.1111/imr.13242
DOI: 10.1111/imr.13242
PubMed id: 37435963
